NCT06140108View on ClinicalTrials.gov

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

June 30, 2024

Conditions

Polycystic Ovary SyndromeWeight GainHbA1c

Interventions

DRUG

Empagliflozin 10 MG

Each participant will receive empagliflozin 10mg daily for 6 months.

DRUG

MetFORMIN 500 Mg Oral Tablet

Each participant will receive metformin 1000mg daily for 6 months.

Trial Locations (1)

74800

SINA Yousuf Sb Goth, Karachi

All Listed Sponsors

lead

SINA Health Education and Welfare Trust

OTHER

NCT06140108 - Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity | Biotech Hunter | Biotech Hunter